DeepMed Research

BARBARA ANN KARMANOS CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1995-01-01

Employees: 5K

Market Cap: -

Website: http://www.karmanos.org

Clinical Trials

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 1

Completed

Conditions: Stage IV Prostate Cancer
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Adenocarcinoma of the Prostate

Interventions: Drug: docetaxel
Drug: pasireotide
Drug: prednisone

First Posted Date: 2011-11-09

Last Posted Date: 2021-03-25

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 18

Registration Number: NCT01468532

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)

Phase 1

Completed

Conditions: Cancer of Pancreas
Cancer of Colon
Pancreatic Cancer
Malignant Tumor of Colon
Pancreatic Neoplasm
Colorectal Cancer
Malignant Neoplasm of Large Intestine
Colon Carcinoma

Interventions: Drug: FOLFOX6
Biological: EGFRBi armed ATC Infusions

First Posted Date: 2011-08-22

Last Posted Date: 2023-05-06

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 15

Registration Number: NCT01420874

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Integration of Neutron Therapy in the Treatment Plan for Stage III Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Withdrawn

Conditions: Lung Cancer

First Posted Date: 2011-08-15

Last Posted Date: 2012-08-22

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT01416961

Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET)

Not Applicable

Conditions: Neuroblastoma

Interventions: Device: FLT-PET

First Posted Date: 2011-03-04

Last Posted Date: 2017-04-06

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 50

Registration Number: NCT01308905

Locations: 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Phase 2

Completed

Conditions: Stage IV Prostate Cancer
Hormone-resistant Prostate Cancer
Adenocarcinoma of the Prostate
Recurrent Prostate Cancer

Interventions: Drug: Hsp90 inhibitor STA-9090
Other: laboratory biomarker analysis
Genetic: polymerase chain reaction
Other: enzyme-linked immunosorbent assay
Genetic: RNA analysis
Other: spectrophotometry
Genetic: reverse transcriptase-polymerase chain reaction
Genetic: gene expression analysis

First Posted Date: 2011-01-05

Last Posted Date: 2018-09-18

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 18

Registration Number: NCT01270880

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
University of Medicine nd Denistry of New Jersey, Piscataway, New Jersey, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

and more 1 locations

Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Denileukin Diftitox (Ontak)

First Posted Date: 2010-12-02

Last Posted Date: 2017-06-20

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 2

Registration Number: NCT01251952

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT

Phase 2

Completed

Conditions: Hematological Malignancies

Interventions: Drug: Tacrolimus and Thymoglobulin

First Posted Date: 2010-11-23

Last Posted Date: 2018-06-18

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 21

Registration Number: NCT01246206

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Drug: zoledronate therapy
Device: PET Scan

First Posted Date: 2010-09-20

Last Posted Date: 2019-04-12

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 11

Registration Number: NCT01205646

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Biological: HER2Bi-armed activated T cells
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: paclitaxel
Other: laboratory biomarker analysis
Procedure: neoadjuvant therapy
Procedure: therapeutic conventional surgery

First Posted Date: 2010-06-22

Last Posted Date: 2023-04-27

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 8

Registration Number: NCT01147016

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Phase 2

Terminated

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Graft Versus Host Disease
Lymphoproliferative Disorder
Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

Interventions: Biological: anti-thymocyte globulin
Biological: rituximab
Drug: sirolimus
Drug: tacrolimus
Other: laboratory biomarker analysis
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: management of therapy complications
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2010-05-04

Last Posted Date: 2019-03-26

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 4

Registration Number: NCT01116232

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy